Type I interferons act as gatekeepers against viral infection, and autoantibodies that neutralize these signaling molecules have been associated with COVID-19 severity and adverse reactions to the live-attenuated yellow fever vaccine. On this background, we sought to examine whether autoantibodies against type I interferons were associated with adverse events following COVID-19 vaccination. Our nationwide analysis suggests that type I interferon autoantibodies were not associated with adverse events after mRNA or viral-vector COVID-19 vaccines.

中文翻译：

---

I 型干扰素自身抗体阳性与 COVID-19 疫苗不良反应之间没有联系

I 型干扰素充当病毒感染的守门人，中和这些信号分子的自身抗体与 COVID-19 的严重程度和黄热病减毒活疫苗的不良反应有关。在此背景下，我们试图研究 I 型干扰素自身抗体是否与 COVID-19 疫苗接种后的不良事件相关。我们的全国性分析表明，I 型干扰素自身抗体与 mRNA 或病毒载体 COVID-19 疫苗后的不良事件无关。